{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:26:59Z","timestamp":1791419219743,"version":"4.3.3"},"reference-count":30,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T00:00:00Z","timestamp":1519084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Sacubitril\/valsartan is indicated for the treatment of heart failure and reduced ejection fraction (HFrEF). Furosemide, a loop diuretic commonly used for the treatment of HFrEF, may be coadministered with sacubitril\/valsartan in clinical practice. The effect of sacubitril\/valsartan on the pharmacokinetics and pharmacodynamics of furosemide was evaluated in this open label, two\u2010period, single\u2010sequence study in healthy subjects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All subjects (<jats:italic>n<\/jats:italic> = 28) received 40\u00a0mg oral single\u2010dose furosemide during period 1, followed by a washout of 2\u00a0days. In period 2, sacubitril\/valsartan 200\u00a0mg (97\/103\u00a0mg) was administered twice daily for 5\u00a0days and a single dose of 40\u00a0mg furosemide was coadministered on day 6. Serial plasma and urine samples were collected to determine the pharmacokinetics of furosemide and sacubitril\/valsartan and the pharmacodynamics of furosemide. The point estimates and the associated 90% confidence intervals for pharmacokinetic parameters were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Coadministration of furosemide with sacubitril\/valsartan decreased the maximum observed plasma concentration (C<jats:sub>max<\/jats:sub>) [estimated geometric mean ratio (90% confidence interval): 0.50 (0.44, 0.56)], area under the plasma concentration\u2013time curve (AUC) from time 0 to infinity [0.72 (0.67, 0.77)] and 24\u2010h urinary excretion of furosemide [0.74 (0.69, 0.79)]. When coadministered with sacubitril\/valsartan, 0\u20134\u2010h, 4\u20138\u2010h and 0\u201324\u2010h diuresis in response to furosemide was reduced by ~7%, 21% and 0.2%, respectively, while natriuresis was reduced by ~ 28.5%, 7% and 15%, respectively. <jats:italic>Post hoc<\/jats:italic> analysis of the pivotal phase III Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM\u2010HF) indicated that the median furosemide dose was similar at baseline and at the end of the study in the sacubitril\/valsartan group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Sacubitril\/valsartan reduced plasma C<jats:sub>max<\/jats:sub> and AUC and 24\u2010h urinary excretion of furosemide, while not significantly affecting its pharmacodynamic effects in healthy subjects.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13505","type":"journal-article","created":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T14:02:38Z","timestamp":1515592958000},"page":"926-936","source":"Crossref","is-referenced-by-count":16,"title":["Effect of the angiotensin receptor\u2013neprilysin inhibitor sacubitril\/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide"],"prefix":"10.1111","volume":"84","author":[{"given":"Surya","family":"Ayalasomayajula","sequence":"first","affiliation":[{"name":"Novartis Institutes for BioMedical Research  East Hanover NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Schuehly","sequence":"additional","affiliation":[{"name":"Translational Medicine, Novartis Institutes for BioMedical Research Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parasar","family":"Pal","sequence":"additional","affiliation":[{"name":"Biostatistical Sciences Novartis Healthcare Pvt. Ltd.  Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Chen","sequence":"additional","affiliation":[{"name":"Clinical Development Novartis Pharmaceuticals  East Hanover NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research  East Hanover NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangadhar","family":"Sunkara","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research  East Hanover NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8563-7048","authenticated-orcid":false,"given":"Thomas H.","family":"Langenickel","sequence":"additional","affiliation":[{"name":"Translational Medicine, Novartis Institutes for BioMedical Research Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108013250501"},{"key":"e_1_2_9_3_1","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.2147\/DDDT.S84782","article-title":"Spotlight on valsartan\u2010sacubitril fixed\u2010dose combination for heart failure: the evidence to date","volume":"10","author":"Vilela\u2010Martin JF","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013748"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00010a014"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.068536"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M177"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/1074248413497257"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199018050-00004"},{"key":"e_1_2_9_11_1","first-page":"1308","article-title":"Furosemide in the long\u2010term management of heart failure: the good, the bad, and the uncertain","volume":"44","author":"Weber KT","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(96)00465-1"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00409-8"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1388-9842(00)00130-6"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.123144"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2008.01.015"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.06.034"},{"key":"e_1_2_9_18_1","unstructured":"Center for Drug Evaluation and Research (CDER) UDoHaHS Food and Drug Administration.Draft guidance for industry drug interaction studies \u2212 study design data analysis implications for dosing and labeling recommendations. Docket No FDA\u20102006\u2010D\u20100036 2012."},{"key":"e_1_2_9_19_1","unstructured":"Committee for Human Medicinal Products (CHMP) EMA.Guideline on the investigation of drug interactions. London UK;2012."},{"key":"e_1_2_9_20_1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4172\/2167-065X.1000147","article-title":"Assessment of drug interaction potential between LCZ696, an angiotensin receptor neprilysin inhibitor, and digoxin or warfarin","volume":"4","author":"Ayalasomayajula S","year":"2015","journal-title":"Clin Pharmacol Biopharm"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009343932"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hft052"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13877"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13883"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13878"},{"key":"e_1_2_9_27_1","unstructured":"Entresto\u00ae EMA SmPC. Available athttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/004062\/WC500197536.pdf(last accessed 21 August 2017)."},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.008938"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050303"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2010.111"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.08484"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13505","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13505","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T09:05:31Z","timestamp":1695546331000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,20]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/bcp.13505"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13505","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,20]]}}}